Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation

Background: Gene regulation of the bone repressor sclerostin (SOST) is only poorly understood. Results: SOST gene suppression by parathyroid hormone is partially mediated by HDAC5 inhibiting MEF2, and SOST gene expression requires class I HDAC activity. Conclusion: SOST gene expression is negatively regulated by HDAC5 and positively by class I HDACs. Significance: Class I HDAC inhibitors represent a novel approach for bone forming osteoporosis therapies. Adult bone mass is controlled by the bone formation repressor sclerostin (SOST). Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves SOST expression reduction by inhibiting myocyte enhancer factor 2 (MEF2), which activates a distant bone enhancer. Here, we extended our SOST gene regulation studies by analyzing a role of class I and IIa histone deacetylases (HDACs), which are known regulators of MEF2s. Expression analysis using quantitative PCR (qPCR) showed high expression of HDACs 1 and 2, lower amounts of HDACs 3, 5, and 7, low amounts of HDAC4, and no expression of HDACs 8 and 9 in constitutively SOST-expressing UMR106 osteocytic cells. PTH-induced Sost suppression was associated with specific rapid nuclear accumulation of HDAC5 and co-localization with MEF2s in nuclear speckles requiring serine residues 259 and 498, whose phosphorylations control nucleocytoplasmic shuttling. Increasing nuclear levels of HDAC5 in UMR106 by blocking nuclear export with leptomycin B (LepB) or overexpression in transient transfection assays inhibited endogenous Sost transcription and reporter gene expression, respectively. This repressor effect of HDAC5 did not require catalytic activity using specific HDAC inhibitors. In contrast, inhibition of class I HDAC activities and expression using RNA interference suppressed constitutive Sost expression in UMR106 cells. An unbiased comprehensive search for involved HDAC targets using an acetylome analysis revealed several non-histone proteins as candidates. These findings suggest that PTH-mediated Sost repression involves nuclear accumulation of HDAC inhibiting the MEF2-dependent Sost bone enhancer, and class I HDACs are required for constitutive Sost expression in osteocytes.

[1]  E. Thomas,et al.  Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors , 2014, Pharmaceuticals.

[2]  Heather L. Plasterer,et al.  Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia , 2012, Journal of child neurology.

[3]  Jennifer J Westendorf,et al.  Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.

[4]  R. Gopalakrishnan,et al.  HDAC3 and HDAC7 Have Opposite Effects on Osteoclast Differentiation* , 2011, The Journal of Biological Chemistry.

[5]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  A. Younes,et al.  The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism , 2010, British journal of haematology.

[7]  E. Verdin,et al.  Regulatory signal transduction pathways for class IIa histone deacetylases. , 2010, Current opinion in pharmacology.

[8]  C. Löwik,et al.  Sclerostin: Current Knowledge and Future Perspectives , 2010, Calcified Tissue International.

[9]  Xiang Xu,et al.  HDAC2 Promotes eIF4E Sumoylation and Activates mRNA Translation Gene Specifically* , 2010, The Journal of Biological Chemistry.

[10]  O. Leupin,et al.  Does osteocytic SOST suppression mediate PTH bone anabolism? , 2010, Trends in Endocrinology & Metabolism.

[11]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[12]  W. Liu,et al.  A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. , 2009, The Journal of clinical investigation.

[13]  Jong-Ho Lee,et al.  Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. , 2009, European journal of pharmacology.

[14]  S. Altamura,et al.  Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. , 2009, Journal of medicinal chemistry.

[15]  Yurii S. Aulchenko,et al.  Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies , 2009, Nature Genetics.

[16]  A. Lassar,et al.  Parathyroid Hormone-Related Peptide Represses Chondrocyte Hypertrophy through a Protein Phosphatase 2A/Histone Deacetylase 4/MEF2 Pathway , 2009, Molecular and Cellular Biology.

[17]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[18]  G. Loots,et al.  Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Florian Diehl,et al.  HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. , 2009, Blood.

[20]  Minoru Yoshida,et al.  14-3-3 regulates the nuclear import of class IIa histone deacetylases. , 2008, Biochemical and biophysical research communications.

[21]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[22]  N. Bertos,et al.  Histone deacetylases as transducers and targets of nuclear signaling , 2008, Journal of cellular biochemistry.

[23]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  A. Kalita,et al.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[25]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[26]  F. Natt,et al.  Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[28]  Yong-Jun Kwon,et al.  High-Content Classification of Nucleocytoplasmic Import or Export Inhibitors , 2007, Journal of biomolecular screening.

[29]  W. Link,et al.  An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. , 2007, Assay and drug development technologies.

[30]  Mark L. Johnson,et al.  The Wnt signaling pathway and bone metabolism , 2007, Current opinion in rheumatology.

[31]  G. Karsenty,et al.  In vivo analysis of Wnt signaling in bone. , 2007, Endocrinology.

[32]  H. Ryoo,et al.  Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis , 2007, Experimental & Molecular Medicine.

[33]  John McAnally,et al.  MEF2C transcription factor controls chondrocyte hypertrophy and bone development. , 2007, Developmental cell.

[34]  Minghong Xu,et al.  Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2 , 2006, Molecular and Cellular Biology.

[35]  D. Trouche,et al.  Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression , 2006, Molecular and Cellular Biology.

[36]  L. Laimins,et al.  Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src , 2006, Oncogene.

[37]  P. Chiao,et al.  Regulation of Nuclear Translocation of HDAC3 by IκBα Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor γ Function* , 2006, Journal of Biological Chemistry.

[38]  J. Westendorf,et al.  Histone Deacetylase Inhibitors Promote Osteoblast Maturation , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  R. Jilka,et al.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.

[40]  T. Hotokebuchi,et al.  Inhibition of Histone Deacetylase Suppresses Osteoclastogenesis and Bone Destruction by Inducing IFN-β Production1 , 2005, The Journal of Immunology.

[41]  M. Kneissel,et al.  SOST is a target gene for PTH in bone. , 2005, Bone.

[42]  Bart O. Williams,et al.  Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.

[43]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[44]  Zhenguo Wu,et al.  Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.

[45]  D. Ovcharenko,et al.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. , 2005, Genome research.

[46]  Xiang-Jiao Yang,et al.  Association with Class IIa Histone Deacetylases Upregulates the Sumoylation of MEF2 Transcription Factors , 2005, Molecular and Cellular Biology.

[47]  E. Olson,et al.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. , 2005, The Journal of clinical investigation.

[48]  B. Harrison,et al.  The CRM1 Nuclear Export Receptor Controls Pathological Cardiac Gene Expression , 2004, Molecular and Cellular Biology.

[49]  John M. Shelton,et al.  Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis , 2004, Cell.

[50]  John A Latham,et al.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.

[51]  A. Kukita,et al.  Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. , 2003, Blood.

[52]  Hui Li,et al.  SMRTe Inhibits MEF2C Transcriptional Activation by Targeting HDAC4 and 5 to Nuclear Domains* , 2001, The Journal of Biological Chemistry.

[53]  E. Olson,et al.  Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.

[54]  M. Yanagida,et al.  Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. , 1998, Experimental cell research.

[55]  J. Mellors,et al.  INHIBITORS OF HISTONE DEACETYLASES : CORRELATION BETWEEN ISOFORM SPECIFICITY AND REACTIVATION OF HIV-1 FROM LATENTLY INFECTED CELLS * , 2011 .

[56]  H. Ryoo,et al.  Modulation of the resorption and osteoconductivity of alpha-calcium sulfate by histone deacetylase inhibitors. , 2010, Biomaterials.

[57]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[58]  中村 隆弘 Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production , 2005 .

[59]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.

[60]  David D. McDonald,et al.  Programs , 1984, CL.